Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BARD1 E287fs |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 | |
| BARD1 E287fs | neuroblastoma | predicted - sensitive | Olaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs in culture but did not delay tumor growth in a cell line xenograft model (PMID: 37688570). | 37688570 | |
| BARD1 E287fs | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 E287fs culture (PMID: 37688570). | 37688570 |